Radanstobart
Based on 1 Customer Validation
Radanstobart (HFB-200603) is a humanized monoclonal antibody targeting CD272 with antitumor activity. Radanstobart is of the human IgG4κ isotype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
For research use only. We do not sell to patients.
- Purity : 99.12%
- CAS No.: 3064483-12-8
- Molecular Weight:146.054 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
Gene ID
Accession
Target
BTLA/CD272
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD272 Protein, Human (HEK293, HY-P7678) can bind Radanstobart. The ED50 for this effect is 21.77 ng/mL.
Chemical Information
-
CAS No. 3064483-12-8
-
Appearance Liquid
-
Molecular Weight 146.054 kDa
-
Color Colorless to light yellow
-
SMILES
[Radanstobart]
-
Synonyms
HFB-200603
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (254 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)